|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
AMBASSADOR Trial: Extended Follow-Up on Adjuvant Pembrolizumab in Bladder Cancer
|
|
Andrea Apolo, MD
|
| Andrea Apolo discusses extended follow-up data from the AMBASSADOR trial. This phase 3 study evaluates adjuvant pembrolizumab versus observation in high-risk muscle-invasive urothelial carcinoma. With 45-month follow-up, pembrolizumab demonstrates significant improvement in disease-free survival.
|
|
|
|
|
|
|
|
|
|
|
|
| Pembrolizumab + Chemoradiation vs. Trimodality Therapy for Muscle-Invasive Bladder Cancer: The KEYNOTE-992 Trial |
| Neal Shore, MD, FACS |
| Sam Chang interviews Neal Shore about the KEYNOTE-992 trial comparing immunotherapy combined with chemoradiation to standard trimodality therapy for muscle-invasive bladder cancer. Dr. Shore explains that the trial evaluates Pembrolizumab with chemoradiation versus placebo with chemoradiation in patients suitable for bladder-sparing approaches. |
|
|
|
|
|
|
|
|
|
|
|
| Phase 2 Trial: Chemotherapy Plus Immunotherapy Facilitates Bladder Sparing in Muscle-Invasive Bladder Cancer |
| Matthew Galsky, MD |
| Ashish Kamat and Matthew Galsky discuss a phase 2 trial on organ sparing for muscle-invasive bladder cancer, published in Nature Medicine. Dr. Galsky highlights the trial's focus on systemic therapy as an alternative to cystectomy, noting its potential for curative outcomes. |
|
|
|
|
|
|
|
|
|
|
|
| A New Era in the Perioperative Management of Muscle-Invasive Bladder Cancer
|
| Max R. Kates, MD
|
| Max Kates discussed two pivotal studies that could significantly alter the treatment landscape for muscle-invasive bladder cancer. The AMBASSADOR trial demonstrated that adjuvant pembrolizumab provides a notable disease-free survival benefit, while an AI model developed by Dr. Faltas’s lab improved predictions of treatment response to neoadjuvant chemotherapy, potentially enabling more patients to undergo bladder preservation.
|
|
|
|
|
|
| Perioperative Sacituzumab Govitecan Alone or in Combination with Pembrolizumab for Patients with Muscle-Invasive Urothelial Bladder Cancer: SURE-01/02 Interim Results
|
| Antonio Cigliola, MD
|
| Antonio Cigliola presents the interim results from the SURE-01 trial, investigating the perioperative use of sacituzumab govitecan (SG) in patients with muscle-invasive urothelial carcinoma. The trial found a pathologic complete response rate of 36.4% among those undergoing radical cystectomy, with an overall treatment-related adverse event rate of 81%.
|
|
|
|
|
|
|
|
|
|
|
| First Results of NURE-Combo: A Phase 2 Study of Neoadjuvant Nivolumab and Nab-Paclitaxel Followed by Postsurgical Adjuvant NIVO in Patients with Muscle-Invasive Bladder Cancer |
| Chiara Mercinelli, MD |
| Chiara Mercinelli presents the first results of the NURE-Combo trial, a Phase 2 study assessing the combination of neoadjuvant nivolumab and nab-paclitaxel followed by postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer. The study included 31 patients, with a notable pathologic complete response (pCR) rate of 38.7% and a major pathological response rate of 73%. |
|
|
|
|
|
| Real-World Characteristics and Outcomes in Patients with Muscle-Invasive Urothelial Carcinoma Treated with Adjuvant Nivolumab with or Without Neoadjuvant Chemotherapy |
| Hedyeh Ebrahimi, MD, MPH |
| Hedyeh Ebrahimi presented findings from a real-world study analyzing the outcomes of patients with MIUC treated with adjuvant nivolumab, with or without prior neoadjuvant chemotherapy. Dr. Ebrahimi emphasized the need for longer follow-up and adjustment for confounding factors to better understand these outcomes and support the integration of NAC as a standard treatment approach for high-risk MIUC patients before adjuvant nivolumab. |
|
|
|
|
|
| STAR-EV: Stereotactic Treatment with Neoadjuvant Radiotherapy and Enfortumab Vedotin: A Phase I/II Study for Localized, Cisplatin Ineligible, Muscle-Invasive Bladder Cancer
|
| Tian Zhang, MD
|
| Tian Zhang presents the STAR-EV study, a phase I/II trial investigating the combination of stereotactic body radiotherapy (SBRT) and enfortumab vedotin for localized MIBC in patients who are ineligible for cisplatin-based chemotherapy. Dr. Zhang emphasized that the outcomes from this study could generate hypotheses for future trials and contribute to the evolving landscape of bladder cancer treatment.
|
|
|
|
|
|
| Dynamic Monitoring of Circulating Tumor DNA to Predict Prognosis in Muscle-Invasive Bladder Cancer Patients After Radical Cystectomy |
| Lourdes Mengual, PhD |
| Lourdes Mengual presents a study on the use of circulating tumor DNA (ctDNA) as a prognostic biomarker in muscle-invasive bladder cancer patients following radical cystectomy. The research found that ctDNA status is a reliable indicator of tumor progression and cancer-specific survival, outperforming traditional imaging methods in early detection of recurrence. |
|
|
|
|
|
